## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*   2. Issuer Name and Ticker or Trading Symbol   5. Relationship of Reporting Person(s) to Issuer     Kenney Richard T   Sonnet BioTherapeutics Holdings, Inc. [SONN]   5. Relationship of Reporting Person(s) to Issuer     (Last)   (First)   (Middle)     100 OVERLOOK CENTER, SUITE 102   3. Date of Earliest Transaction (Month/Day/Year)   6. Individual or Joint/Group Filing (Check Applicable Line)     (Street)   PRINCETON, NJ   08540   4. If Amendment, Date of Original Filed (Month/Day/Year)   6. Individual or Joint/Group Filing (Check Applicable Line)     X   Form filed by One Reporting Person   Form filed by More than One Reporting Person			Table I - Non-	Derivative Securities Acquired, Disposed of, or Beneficia	ally Owned			
Kenney Richard T   Sonnet BioTherapeutics Holdings, Inc. [SONN]   (Check all applicable)     (Last)   (First)   (Middle)     100 OVERLOOK CENTER, SUITE 102   A. If Amendment, Date of Original Filed (Month/Day/Year)   6. Individual or Joint/Group Filing (Check Applicable Line)     (Street)   X   Form filed by One Reporting Person	(City)	(State)	(Zip)					
Kenney Richard T Sonnet BioTherapeutics Holdings, Inc. [SONN] (Check all applicable)   (Last) (First) (Middle)	( )	NJ	08540	4. If Amendment, Date of Original Filed (Month/Day/Year)	X Form filed by One Reporting Person			
Kenney Richard T Sonnet BioTherapeutics Holdings, Inc. [SONN] (Check all applicable)   3. Date of Earliest Transaction (Month/Day/Year) Director 10% Owner   3. Date of Earliest Transaction (Month/Day/Year) Officer (give title Other (specify	100 OVERLOOK CENTER, SUITE 102				Chief Medical Officer			
Kenney Richard T Sonnet BioTherapeutics Holdings, Inc. [SONN] (Check all applicable)	(Last)	(First)	(Middle)	, , , , , , , , , , , , , , , , , , ,	V Officer (give title Other (specify			
			erson*	2. Issuer Name and Ticker or Trading Symbol Sonnet BioTherapeutics Holdings, Inc. [ SONN ]				

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	07/11/2025		Α		8,000	A	(1)	9,374 <sup>(2)(3)</sup>	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 3. Transaction 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount of 8. Price of 9. Number of 10. 11. Nature Derivative Conversion Execution Date Transaction Derivative Expiration Date ecurities Underlying Derivative derivative Ownership of Indirect Date if any (Month/Day/Year) Security (Instr. 3) or Exercise Price of (Month/Dav/Year (Month/Dav/Year) **Derivative Security** Code (Instr. Securities Security Securities Form: Beneficial 8) Acquired (A) (Instr. 3 and 4) (Instr. 5) Beneficially Direct (D) Ownership Derivative or Disposed of Owned or Indirect (Instr. 4) Security (D) (Instr. 3, 4 Following (I) (Instr. 4) and 5) Reported Transaction(s) (Instr. 4) Amount or Date Expiration Number v Code (A) (D) Exercisable Date Title of Shares

Explanation of Responses:

1. On July 11, 2025, the Reporting Person was granted 8,000 restricted stock units, which will be settled in shares of common stock, par value \$0.0001. The restricted stock units vest as to 100% of the restricted stock units on the earlier of (i) January 8, 2026, or (ii) the date of a "Change in Control" (as defined under the Issuer's 2020 Omnibus Equity Incentive Plan).

2. Includes unvested restricted stock units.

3. All amounts reflect the Issuer's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.

/s/ Richard T. Kenney

\*\* Signature of Reporting Person

07/15/2025

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.